BASIC PRINCIPLES OF DYNAMIC CONTRAST-ENHANCED MAGNETIC RESONANCE IMAGING IN THE EVALUATION OF THE PREOPERATIVE CHEMOTHERAPY IN PATIENTS WITH BONE AND SOFT TISSUE SARCOMAS

Cover Page

Cite item

Full Text

Abstract

Magnetic resonance imaging (MRI) is widely used (method of choice) in therapy monitoring and in further dynamic control. MRI allows to evaluate changes in tumor size and structure during the treatment. However, as a result of heterogeneity in structure of bone and soft tissue sarcomas, these criteria don't allow to determine the effect of treatment properly in all clinical cases. This happens because this method doesn't reflect the most important criteria - the tumor vascularization and changes in vascularization during treatment. Thus, a new physiological method of MRI such as dynamic contrast-enhanced MRI (DCE MRI) is being developed. DCE MRI provides the better evaluation of response to preoperative treatment due to its ability in detection of highly vascularized zones in different sites of the tumor, which correlate with regions of viable tumor on pathologic examination. DCE MRI provides different types of analyses of tumor changes during therapy: quantitative, semi-qualitative and qualitative. The following review of literature demonstrates the basic principles of DCE MRI in assessing the efficacy of treatment in patients with bone and soft tissue sarcomas.

About the authors

Российский онкологический научный центр им. Н.Н. Блохина РАМН

Author for correspondence.
Russian Federation

Российский онкологический научный центр им. Н.Н. Блохина РАМН

Email: yzamogilnaya@gmail.com
Russian Federation

Российский онкологический научный центр им. Н.Н. Блохина РАМН

Russian Federation

Российский онкологический научный центр им. Н.Н. Блохина РАМН;
РМАПО

Russian Federation

Российский онкологический научный центр им. Н.Н. Блохина РАМН

Russian Federation

Российский онкологический научный центр им. Н.Н. Блохина РАМН

Russian Federation

Российский онкологический научный центр им. Н.Н. Блохина РАМН

Russian Federation

ФГУ Московский научно-исследовательский онкологический институт им. П.А. Герцена
Минздравсоцразвития России

Russian Federation

Российский онкологический научный центр им. Н.Н. Блохина РАМН

Russian Federation

A. B. Bludov

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

Y. A. Zamogilnaya

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

A. S. Nered

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

N. V. Kochergina

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences;
Russian Medical Academy of Postgraduate
Education

Russian Federation

B. Y. Bokhyan

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

G. N. Machak

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

A. A. Fedenko

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

O. A. Anurova

P.A Herzen Moscow Research Oncological Institute

Russian Federation

O. A. Zaspa

N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2011 ., ., ., ., ., ., ., ., ., Bludov A.B., Zamogilnaya Y.A., Nered A.S., Kochergina N.V., Bokhyan B.Y., Machak G.N., Fedenko A.A., Anurova O.A., Zaspa O.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-66671 от  09.11.2009.